Amicus Therapeutics Inc. (NASDAQ:FOLD)’s share price rose 4.7% during trading on Friday . The company traded as high as $6.03 and last traded at $5.96, with a volume of 966,127 shares. The stock had previously closed at $5.69.

FOLD has been the topic of a number of recent research reports. Chardan Capital raised their price objective on Amicus Therapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, April 12th. Bank of America Corp. initiated coverage on Amicus Therapeutics in a research note on Wednesday, May 18th. They set a “buy” rating and a $10.00 price objective on the stock. Robert W. Baird assumed coverage on Amicus Therapeutics in a research note on Wednesday, April 13th. They set a “neutral” rating and a $9.00 price objective on the stock. Goldman Sachs Group Inc. assumed coverage on Amicus Therapeutics in a report on Wednesday, March 30th. They issued a “neutral” rating and a $10.00 target price on the stock. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $19.00 target price (up previously from $17.00) on shares of Amicus Therapeutics in a report on Tuesday, June 14th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $12.88.

The stock’s market cap is $755.94 million. The firm’s 50 day moving average is $6.16 and its 200-day moving average is $7.03.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.01. On average, analysts forecast that Amicus Therapeutics Inc. will post ($1.35) earnings per share for the current year.

In other Amicus Therapeutics news, General Counsel Ellen Rosenberg bought 15,000 shares of the stock in a transaction on Thursday, June 2nd. The shares were acquired at an average price of $7.67 per share, with a total value of $115,050.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

A number of large investors have modified their holdings of the stock. Nationwide Fund Advisors boosted its stake in shares of Amicus Therapeutics by 1.7% in the fourth quarter. Nationwide Fund Advisors now owns 105,597 shares of the biopharmaceutical company’s stock worth $1,024,000 after buying an additional 1,754 shares during the last quarter. ProShare Advisors LLC boosted its stake in shares of Amicus Therapeutics by 15.6% in the fourth quarter. ProShare Advisors LLC now owns 117,318 shares of the biopharmaceutical company’s stock worth $1,138,000 after buying an additional 15,789 shares during the last quarter. Swiss National Bank boosted its stake in shares of Amicus Therapeutics by 3.8% in the fourth quarter. Swiss National Bank now owns 140,200 shares of the biopharmaceutical company’s stock worth $1,360,000 after buying an additional 5,100 shares during the last quarter. TD Asset Management Inc. boosted its stake in shares of Amicus Therapeutics by 1.5% in the fourth quarter. TD Asset Management Inc. now owns 178,700 shares of the biopharmaceutical company’s stock worth $1,733,000 after buying an additional 2,600 shares during the last quarter. Finally, Columbus Circle Investors boosted its stake in shares of Amicus Therapeutics by 122.7% in the fourth quarter. Columbus Circle Investors now owns 227,889 shares of the biopharmaceutical company’s stock worth $2,211,000 after buying an additional 125,574 shares during the last quarter.

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.